Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug niraparib tested before prostate surgery in small trial

NCT ID NCT04030559

Terminated Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated Jun 20, 2026 · Updated 5 times

Summary

This phase II trial tested the drug niraparib in 11 men with high-risk prostate cancer that had not spread. The drug was given before standard surgery to see if it could eliminate tumor cells. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Niraparib (a PARP inhibitor drug, brand name Zejula)

What this could lead to

If it works, this could point toward a new treatment option for men with high-risk prostate cancer who have specific genetic mutations.

What could go wrong

This was a very small, early-phase trial with only 11 participants, and it was terminated early. Results may not be reliable or apply to all patients.

Conditions

The condition(s) this trial relates to.

BRCA2-related cancer predisposition CHEK2-related cancer predisposition prostate cancer RAD51C-related cancer predisposition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATM GENE MUTATION BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CDK12 GENE MUTATION CHEK1 GENE MUTATION CHEK2 GENE MUTATION DNA DAMAGE RESPONSE GENE MUTATION DNA REPAIR GENE MUTATION DNA REPAIR GENE MUTATION FANCA GENE MUTATION FANCD2 GENE MUTATION FANCL GENE MUTATION GEN1 GENE MUTATION NBN GENE MUTATION PROSTATE CARCINOMA RAD51 GENE MUTATION RAD51 GENE MUTATION RAD51C GENE MUTATION RAD51C GENE MUTATION RAD51C GENE MUTATION